(NASDAQ: IMAB) I Mab's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
I Mab's earnings in 2025 is -$38,207,000.On average, 9 Wall Street analysts forecast IMAB's earnings for 2025 to be -$19,187,034, with the lowest IMAB earnings forecast at -$18,434,601, and the highest IMAB earnings forecast at -$19,751,359. On average, 9 Wall Street analysts forecast IMAB's earnings for 2026 to be -$62,357,861, with the lowest IMAB earnings forecast at -$90,329,547, and the highest IMAB earnings forecast at -$23,701,630.
In 2027, IMAB is forecast to generate -$90,179,061 in earnings, with the lowest earnings forecast at -$103,233,768 and the highest earnings forecast at -$59,254,076.